Minor dietary components with proven biological effects play an important role in the complex treatment strategy of obesity-related diseases, however our knowledge regarding the mechanisms of their action is relatively limited. The aim of this project is to identify novel mechanisms behind the beneficial effects of omega-3 in patients with type 2 diabetes mellitus (DM), i.e. the only dietary component with clearly demonstrated beneficial effects on dyslipidemia and cardiovascular mortality and morbidity in the diabetic patients.
Based on our results in a mouse model of metabolic syndrome (Kuda et al. 2009. Diabetologia; Horakova et al. 2012. PLoS One; Kus et al. 2011. PLoS One), and by taking advantage of available clinical data and biological materials (plasma, adipose and muscle tissue) collected during the previous randomized, placebo-controlled, intervention study in DM patients treated with metformin (6-month-long intervention; groups, n=15: placebo, omega-3, placebo+pioglitazone, omega-3+pioglitazone), we focus on:
Project will help to understand the mechanisms, by which omega-3 normalize lipid metabolism and mitigate low-grade inflammation in patients with DM, specifically in those treated with metformin (or metformin + pioglitazone). The results will help to
Supported by the Ministry of Health of the Czech Republic (NT13763-4; 2012-2015; PI: Jan Kopecký, MD, DSc; collaborator: prof. Terezie Pelikánová, MD, DSc, Diabetes Centre, IKEM, Prague).